Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Valneva SENASDAQ: VALN

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of €15.22M rose 1.8% year over year, behind the +12.6% change in trailing-twelve-month research & development. Sequentially, it fell 40.5% from the prior quarter. Over 3 fiscal years it compounded at -6.7% a year.

Context

  • Research & development amounted to 48.8% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1.8% toward the trailing-twelve-month pace of +12.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€15.22M-40.5% QoQ
Last fiscal yearDec 2025
€85.3M+15.1% YoY
LTMMar 2026
€85.57M+12.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.8%——
1 year+15.1%——
3-year CAGR-6.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

EUR · from the income statement

Latest · FY2025
85.3M EUR
Year-over-year change
+15.1%
4-year CAGR
-16.2%

Research & Development vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +12.6% is the 3rd highest of 8, against a peer median of -15.0%.
  • Research & development amounts to 54.7% of revenue for VALN, versus a peer median of 138.2%.
VALN Competitors
Research & Development for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
PCVXVaxcyte, Inc.LTM Jun 2026$1.03B USD+74.2%+67.4%—
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
IBRXImmunityBio, Inc.LTM Sep 2026$252.23M USD+33.2%-5.7%138.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$98.25M USD-44.3%-8.8%216.6%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M USD-27.2%-33.9%—
Peer median (excluding VALN) —-15.0%-5.7%138.2%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.